Jardiance (empagliflozin) - Eli Lilly, Boehringer Ingelheim
EmpaCKM: Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors (clinicaltrials.gov) - Sep 26, 2026 - P1 | N=24 | Completed | Sponsor: McGill University | Recruiting ➔ Completed | Trial completion date: Jan 2027 ➔ Apr 2026 | Trial primary completion date: Jan 2027 ➔ Apr 2026 
Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
http://clinicaltrials.gov/ct2/show/NCT06753994
 
Sep 26, 2026
 
Prev Next